Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Canakinumab in Gouty Arthritis (Extension Study)
NCT00927810Phase 2Completed
- Sponsor
- Novartis
- Start
- Jun 2009
- Primary completion
- Aug 2010
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 18
01
Overview
A Phase 2 trial of canakinumab in gouty arthritis, sponsored by Novartis. Started Jun 2009; status: completed.
02
Drugs
canakinumab
03
Conditions
gouty arthritis
Beyond the preview
Go deeper on NCT00927810.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00927810.